Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

3-D Tractography FUS Ablation for Essential Tremor

NCT: NCT06331052 · RECRUITING

NCT IDNCT06331052
StatusRECRUITING
Start Date2024-02-28
Completion2028-02-28
SponsorUniversity of North Carolina, Chapel Hill (OTHER)
First posted
Last updated

Brief Summary

The investigators propose to advance Vim-FUSA (Ventral Intermediate Nucleus - Focused Ultrasound Ablation) with the support of 3-D tractography, a neuroimaging technique to visually represent nerve tracts within the brain. The investigators hypothesize that 3-D tractography Vim-FUSA will improve the Vim ablation compared to standard Vim-FUSA and prove safe and feasible in the clinical setting. The investigators also hypothesize that intraoperative magnetic resonance (i-MR) monitoring will differentiate ablated tissue from immediate perilesional edema and accurately predict the Vim-FUSA clinical outcomes.

Frequently Asked Questions

What is 3-D Tractography FUS Ablation for Essential Tremor?

3-D Tractography FUS Ablation for Essential Tremor is a clinical trial registered under NCT06331052. Current status: RECRUITING.

What is the status of NCT06331052?

The current status of NCT06331052 (3-D Tractography FUS Ablation for Essential Tremor) is: RECRUITING.

When did 3-D Tractography FUS Ablation for Essential Tremor start?

3-D Tractography FUS Ablation for Essential Tremor started on 2024-02-28.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.